Dolac, Ampoules 30 mg, 1 ml, 10 pcs.

Composition

>

1 ml of solution for intravenous and intramuscular administration contains:

Active ingredient-ketorolac trometamine 30 mg;

excipients-sodium chloride,

disodium edetate,

propylene glycol,

buffer solution (potassium dihydrogen phosphate, sodium hydroxide, water for injection),

sodium hydroxide and hydrochloric acid – for pH adjustment,

water for injection.

Pharmacological action

Pharmacological action – analgesic, antiplatelet, antipyretic, anti-inflammatory.

Inhibits cyclooxygenase (mainly in peripheral tissues), inhibits the synthesis of PG-modulators of pain sensitivity, thermoregulation and inflammation.

The analgesic effect develops in 1/2 hour, reaches a maximum in 1-2 hours and lasts 4-6 hours. Inhibits platelet aggregation, reduces the concentration of thromboxane and increases the bleeding time.

Indications

Moderate to severe pain syndrome (short-term relief, mainly in the postoperative period).

Contraindications

Hypersensitivity, including to other drugs. NSAIDs, acute gastric and duodenal ulcers, a history of ulceration, perforation, or gastrointestinal bleeding, moderate to severe renal failure, risk of hypovolemia or dehydration, hemorrhagic stroke, conditions with a high risk of bleeding or incomplete hemostasis, preoperative period and during surgery (due to a high risk of bleeding); concomitant use of other NSAIDs, including non-steroidal anti-inflammatory drugs (NSAIDs). aspirin, as well as pentoxifylline; pregnancy, labor, breastfeeding, age up to 16 years.

Side effects

From the nervous system and sensory organs: headache, dizziness, nervousness, tremor, impaired ability to concentrate, asthenia, depression, hallucinations, paresthesia, convulsions; impaired taste and vision.

Cardiovascular and blood disorders (hematopoiesis, hemostasis): decreased or increased blood pressure, palpitations, anemia, eosinophilia, thrombocytopenia, leukopenia.

From the respiratory system: dyspnoea, cough, bronchospasm, bronchial asthma, pulmonary edema.

From the digestive tract: dry mouth, stomatitis, nausea, vomiting, feeling of fullness of the stomach, flatulence, constipation or diarrhea, dyspepsia, gastritis, peptic ulcers, rectal bleeding, melena.

From the genitourinary system: hematuria, glomerulonephritis, nephrotoxic syndrome, acute renal failure, urinary retention, polyuria, frequent urination.

From the skin: pallor of the skin, itching, rash (including hemorrhagic), soreness at the injection site.

Allergic reactions: anaphylaxis, anaphylactoid reaction, laryngeal edema, tongue edema.

Other: impaired liver function.

Interaction

Acetylsalicylic acid and other NSAIDs mutually increase the risk of severe side effects.

Pentoxifylline and substances that affect hemostasis (warfarin, heparin, dextran) increases the likelihood of bleeding.

Probenecid reduces plasma Cl and volume of distribution, increases plasma concentrations, and increases T 1/2. Reduces the diuretic effect of furosemide. Concomitant use with ACE inhibitors may increase the risk of impaired renal function.

How to take, course of administration and dosage

Inside, iv (jet, for at least 15 seconds), iv (deep into the muscle, slowly). The dose is selected individually, taking into account the severity of the pain syndrome.

Single doses for intravenous administration in patients under 65 years of age — 10-30 mg, every 4-6 hours. Patients older than 65 years or with impaired renal function 10-15 mg, every 4-6 hours IV, patients under 65 years 10-30 mg, every 6 hours (with continuous infusion-the initial dose is 30 mg, then at a rate of 5 mg/h); patients older than 65 years or with impaired renal function-10-15 mg every 6 hours jet. Duration of application is not more than 5 days.

Inside 10 mg up to 4 times a day. The highest daily dose is 40 mg. The course duration is not more than 7 days.

When switching from parenteral administration of the drug to oral administration, the total daily dose of both dosage forms on the day of transfer should not exceed 90 mg for patients under 65 years of age, and 60 mg for patients over 65 years of age or with impaired renal function (while the dose of the drug in tablets should not exceed 30 mg).

Special instructions

Dolak’s solution for injection is incompatible in one syringe with promethazine, hydroxyzine (precipitation occurs); it is compatible with saline,5% glucose solution, Ringer’s solution, Plasmalit solution, as well as with infusion solutions containing aminophylline, lidocaine hydrochloride, dopamine hydrochloride, short-acting human insulin and heparin sodium salt.

Form of production

Solution for intravenous and intramuscular administration.

Storage conditions

Store in a dry place, protected from light, at a temperature of 15-25 °C

Shelf life

2 years

Active ingredient

Ketorolac

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Description

For adults as directed by your doctor

Indications

Osteoarthritis, Cancer, Osteochondrosis, Trigeminal Neuralgia, Arthritis, Sciatica, Osteoarthritis, Bone Fractures, Rheumatoid Arthritis, Periodontitis

Weight

Weight: 40 gr.